{"id":"low-dose-skq1","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Visual disturbances"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SkQ1 (plastoquinone derivative) is designed to cross cell membranes and concentrate in mitochondria due to its lipophilic cationic structure. Once localized to mitochondria, it acts as an antioxidant to scavenge reactive oxygen species (ROS) and reduce oxidative stress, thereby protecting mitochondrial function and cellular viability. This mechanism is intended to slow age-related degeneration and improve outcomes in conditions characterized by mitochondrial dysfunction.","oneSentence":"SkQ1 is a mitochondria-targeted antioxidant that accumulates in mitochondria to neutralize reactive oxygen species and protect against oxidative damage.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:48.721Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Age-related macular degeneration (AMD)"},{"name":"Dry eye disease"}]},"trialDetails":[{"nctId":"NCT03764735","phase":"PHASE3","title":"Study of SkQ1 as Treatment for Dry-eye Syndrome","status":"COMPLETED","sponsor":"Mitotech, SA","startDate":"2018-12-06","conditions":"Dry Eye Syndrome","enrollment":452},{"nctId":"NCT02121301","phase":"PHASE2","title":"A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)","status":"COMPLETED","sponsor":"Mitotech, SA","startDate":"2014-04","conditions":"Keratoconjunctivitis Sicca","enrollment":91}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Visomitin"],"phase":"phase_3","status":"active","brandName":"Low Dose - SkQ1","genericName":"Low Dose - SkQ1","companyName":"Mitotech, SA","companyId":"mitotech-sa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SkQ1 is being studied as a potential treatment for Keratoconjunctivitis Sicca and Dry Eye Syndrome in a clinical trial. The study is comparing the safety and efficacy of a low dose 0.155µg/mL SkQ1 ophthalmic solution to a high dose 1.55µg/mL SkQ1 ophthalmic solution and a placebo solution.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}